ArticleJournal of gastroenterology2026
Comment on: Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease.
Rong Peng et al.PubMed ↗Publisher ↗
No numbers read from the abstract.